There is evidence that low-dose IL-2 therapy can increase the level of Tregs, and because the lack of Tregs may contribute to the pathogenesis of SLE, this may be an effective treatment for SLE (Tahvildari and Dana, 2019). This evidence concerns the gene IL2 and systemic lupus erythematosus.